The Future of Global Biotech

Global research, development, distribution and commercialization of  synthetic cannabinoid and psilocybin drugs

Global pharmaceutical-grade, natural cannabis products
Affordable and accessible medicines globally
Active drug pipelines 14 proprietary compounds

WHO WE ARE

Unlocking transformative therapeutic potential of cannabinoid and psychedelic compounds through application of scientific, development, and finance expertise to the advancement of proprietary treatments for unmet healthcare needs like depression, epilepsy, post-traumatic stress disorder (PTSD), addiction and withdrawal, fibromyalgia, and dermatological disorders.

Pipeline

Research, development, and distribution footprint in 31 markets within North and South America, Asia, and Australia. Agreements with top-tier academic institutions and recognized clinical research organizations (CRO) for drug discovery and trials which will integrate with in-house manufacturing of active pharmaceutical ingredients (API) for scalable commercial sales to the healthcare market.

Share by: